You are here

C. difficile

FDA Approves Merck's Dificid for Infections in Children

FDA Approves Merck's Dificid for Infections in Children

Motley Fool

Flag link:

MGB tops up cash pool to wrap up antibiotic phase 2a

MGB tops up cash pool to wrap up antibiotic phase 2a

Fierce Biotech

clinical trials

Flag link:

Microbiome company Finch raises $53M ahead of anti-infective readout

Microbiome company Finch raises $53M ahead of anti-infective readout

BioCentury

Finch Therapeutics

Flag link:

Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering

Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering

CP Wire

Seres Therapeutics

ulcerative colitis

Flag link:

Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering

Seres Therapeutics

ulcerative colitis

Flag link:

Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile

Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile

CP Wire

Finch Therapeutics

Flag link:

Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile

Finch Therapeutics

Flag link:

Rebiotix to Report on Development of its Microbiome Health Index

Rebiotix to Report on Development of its Microbiome Health Index

CP Wire

Flag link:

Rebiotix to Report on Development of its Microbiome Health Index

Flag link:

Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018

Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018

CP Wire

Flag link:

Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018

Flag link:

Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial

Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial

CP Wire

Summit Therapeutics

microbiome ridinilazole

Flag link:

J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout

J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout

Endpoints

Flag link:

Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report

Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report

Fierce Pharma

Flag link:

Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure

Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure

Endpoints

clinical trials

Flag link:

Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study

Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study

Endpoints

Finch Therapeutics

Flag link:

Pfizer says mid-stage trial for C. difficile vaccine had positive results

Pfizer says mid-stage trial for C. difficile vaccine had positive results

Marketwatch

clinical trials

Flag link:

Facing Cubicin generic threat, Merck's antibiotics biz gets a nudge with new C. diff-fighter Zinplava

Facing Cubicin generic threat, Merck's antibiotics biz gets a nudge with new C. diff-fighter Zinplava

Fierce Pharma

Flag link:

Merck Has An Upcoming PDUFA Date For Bezlotoxumab

Merck Has An Upcoming PDUFA Date For Bezlotoxumab

Yahoo/Benzinga

Flag link:

U.S. regulatory panel backs approval for Merck C. difficile drug

U.S. regulatory panel backs approval for Merck C. difficile drug

Yahoo/Reuters

advisory panels

Flag link:

Pages